ClinicalTrials.gg
TerminatedNCT07121829Updated Aug 14, 2025

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

A Phase 1 interventional study of Tovorafenib and Tovorafenib Drug: Pimasertib in Melanoma, Solid Tumor and Pilocytic Astrocytoma, sponsored by Day One Biopharmaceuticals, Inc.. Terminated at 10 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Day One Biopharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor decision

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.
  • Registered 3 years 2 months after the study started (first participant enrolled May 2022, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
779th of 1,749
44 · median 37
Started
2022
with 87 others
Phase 1
647 of 2,049
54 open now
Registered
1,980th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 779th largest by enrollment of the 1,749 interventional ones that give a count, is one of 88 that started in 2022, is one of 647 in phase 1, and was the 1,980th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of the MAPK pathway, such as tumors that harbor RAS or RAF alterations.

*Note: Study concluded as Phase 1b only.

03

Conditions studied

  • Melanoma
  • Solid Tumor
  • Pilocytic Astrocytoma
  • Non Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • MAP Kinase Family Gene Mutation
  • RAS Mutation
  • RAF Mutation
  • MEK Mutation

Keywords

  • DAY101
  • Mitogen-activated protein kinase
  • tovorafenib
  • pimasertib
  • DAY201
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed by participant ≥12 years of age; either a Consent or an Assent Form will be provided to the patient based on their capacity, local regulations, and guidelines.
  • Participants must have a report of confirmed diagnosis of tumor and a concurrent MAPK pathway alteration (genomic alterations in RAS, RAF, MEK, or NF1) obtained through a tumor or liquid as assessed by genomic sequencing, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), or another clinically accepted molecular diagnostic method recognized by local laboratory or regulatory agency
  • Participants must have radiographically stable, recurrent or progressive disease that is measurable using the appropriate tumor response criteria eg, ( version 1.1, RANO)
  • Archival tumor tissue should be preferably less than 3 years old. If unavailable, a freshly acquired tumor tissue biopsy or liquid biopsy is required
  • If are present, they must have been previously treated and be stable as assessed by radiographic imaging

Exclusion criteria

Exclusion Criteria:

  • Known presence of concurrent activating alterations
  • Participants with current evidence or a history of serous retinopathy (SR), retinal vein occlusion (RVO) or ophthalmopathy present at screening or baseline who would be considered at risk for SR or RVO
  • Participants who have an unstable neurological condition, despite adequate treatment (eg, uncontrolled seizures)
  • Participants with history of acute neurological events (such as intracranial or subarachnoid hemorrhage, stroke, intracranial trauma) within the past 6 months
  • History of second within 3 years prior to study treatment except for curatively treated cervical cancer in situ, non-melanoma skin cancer, or superficial bladder cancer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Tovorafenib plus pimasertib

    Drug: Tovorafenib · Drug: Tovorafenib Drug: Pimasertib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants who will report Treatment emergent adverse events (TEAEs) and serious TEAEs

    Time frame: Up to 30 days after the last dose of any study drug

  2. Number of participants who will report clinically significant changes in vital signs

    Time frame: Up to 30 days after the last dose of any study drug

  3. Number of participants who will report clinically significant changes in clinical chemistry parameters

    Time frame: Up to 30 days after the last dose of any study drug

  4. Number of participants who will report clinically significant changes in hematology parameters

    Time frame: Up to 30 days after the last dose of any study drug

  5. Number of participants with Dose limiting toxicities (DLTs)

    Time frame: Up to 30 days after the last dose of any study drug

Secondary outcomes

  1. Percentage of participants with complete overall response rate (ORR)

    ORR as assessed by the proportion of participants with the best overall confirmed response of complete response (CR) or partial response (PR) according to the appropriate tumor response criteria as assessed by Investigator

    Time frame: Up to 30 months

  2. Duration of response (DOR)

    The interval from the date of the first documentation of tumor response (CR or PR) that was subsequently confirmed by investigator assessment to the date of first occurrence of radiographic disease progression based on appropriate tumor response criteria as assessed by investigator or death due to any cause, whichever occurs earlier.

    Time frame: Up to 30 months

  3. Progression Free Survival (PFS)

    The interval from the date of the first dose to the first occurrence of radiographic disease progression based on appropriate tumor response criteria as assessed by investigator or death due to any cause, whichever occurs earlier.

    Time frame: Up to 30 months

  4. Overall Survival (OS)

    The interval from the date of the first dose until the recorded date of death due to any cause.

    Time frame: Up to 30 months

  5. Time to Response

    Defined in participants with best overall response of CR or PR as determined by Investigator, time to response is defined as the interval from the date of the first dose to date of first documentation of tumor response (CR or PR) that was subsequently confirmed by investigator assessment.

    Time frame: Up to 30 months

  6. Plasma concentration of DAY101

    Time frame: Cycles 1 through Cycle 11 (each cycle is 28 days)

  7. Maximum drug concentration (Cmax) of DAY101

    Time frame: Cycle 1, Day 1 through Cycle 1, Day 22

  8. Area Under the Curve from Time Zero to Last Measurable Concentration (AUC 0-last)

    Time frame: Cycle 1, Day 1 through Cycle 1, Day 22

  9. Change in gene expression levels in pre and post treatment samples using RNA sequencing (RNA seq) analysis.

    Time frame: Up to 30 months

  10. Change in expression levels of phosphorylated ERK (pERK) and Ki67 in pre and post treatment samples using immunohistochemistry methodology.

    Time frame: Up to 30 months

07

Study locations

10 sites
  • The Angeles Clinic
    Los Angeles, California 90025, United States
  • Hoag Health
    Newport Beach, California 92663, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Community North Cancer Center
    Indianapolis, Indiana 46250, United States
  • OHSU Knight Cancer Institute
    Portland, Oregon 97239, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Princess Margaret Cancer Centre
    Toronto, Ontario, Canada
  • The Hospital for Sick Children
    Toronto, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2024, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Aug 14, 2025
StartActual
May 2, 2022
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07121829
Lead sponsor
Day One Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
May 2, 2022
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Last update
Aug 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tovorafenib · Pimasertib

Start the discussion